How should Invega Sustenna (paliperidone palmitate) be initiated and maintained in a stabilized patient with schizophrenia, and what monitoring is required?

Invega Sustenna Initiation and Maintenance

For stabilized patients with schizophrenia, initiate Invega Sustenna with 234 mg deltoid injection on Day 1, followed by 156 mg deltoid injection on Day 8, then continue with monthly maintenance doses of 39-234 mg (recommended 117 mg) in either deltoid or gluteal muscle, with no oral supplementation required. 1

Initiation Protocol

Loading Dose Regimen

• Day 1: 234 mg intramuscular injection into deltoid muscle
• Day 8 (±2 days acceptable): 156 mg intramuscular injection into deltoid muscle
• No oral antipsychotic supplementation needed 1, 2

Needle Selection for Deltoid Injections

• Patients <90 kg: Use 1-inch, 23-gauge needle (blue hub)
• Patients ≥90 kg: Use 1.5-inch, 22-gauge needle (gray hub) 1

Critical Pre-Initiation Step

Establish tolerability first with oral paliperidone or oral risperidone before initiating Invega Sustenna in patients who have never taken these medications 1. This is a crucial safety measure to avoid committing patients to a long-acting formulation if they cannot tolerate the medication.

Maintenance Treatment

Standard Dosing

• Timing: Monthly injections starting 5 weeks after the first injection (±7 days acceptable) 1
• Dose range: 39-234 mg monthly
• Recommended dose: 117 mg monthly for schizophrenia 1
• Injection site: Either deltoid or gluteal muscle (gluteal uses 1.5-inch, 22-gauge needle regardless of weight) 1

Dose Adjustments

Adjust monthly maintenance doses based on tolerability and efficacy within available strengths. Consider the prolonged-release characteristics—full effect of dose adjustments may not be evident for several months 1. The 2025 INTEGRATE guidelines support paliperidone as a second-line option after D2 partial agonist failure 3.

Switching Strategies

From Oral Antipsychotics

• Initiate Invega Sustenna the day after discontinuing oral antipsychotic
• Use standard loading dose regimen (234 mg Day 1,156 mg Day 8)
• Gradually discontinue previous oral antipsychotic at time of Invega Sustenna initiation 1, 4

Dose equivalency from oral paliperidone to Invega Sustenna maintenance:

• Oral 12 mg daily → 234 mg monthly
• Oral 9 mg daily → 156 mg monthly
• Oral 6 mg daily → 117 mg monthly
• Oral 3 mg daily → 39-78 mg monthly 1

From Other Long-Acting Injectables

• No loading doses required
• Initiate Invega Sustenna at the time of the next scheduled injection of previous LAI
• Continue monthly thereafter
• Select maintenance dose based on previous clinical history of tolerability/efficacy 1

Managing Missed Doses

Missed Second Initiation Dose (Day 8)

<4 weeks since first injection:

• Give 156 mg deltoid immediately
• Give third injection of 117 mg at 5 weeks after first injection (regardless of second injection timing)
• Resume monthly dosing thereafter 1

4-7 weeks since first injection:

• Give 156 mg deltoid immediately
• Give second 156 mg deltoid 1 week later
• Resume monthly dosing thereafter 1

>7 weeks since first injection:

• Restart with full loading regimen (234 mg Day 1,156 mg Day 8) 1

Missed Maintenance Dose

4-6 weeks since last injection:

• Resume at previously stabilized dose immediately
• Continue monthly intervals 1

>6 weeks to 6 months since last injection:

• Give deltoid injection at previous dose immediately (unless previously on 234 mg, then use 156 mg)
• Give second deltoid injection 1 week later at same dose
• Resume monthly dosing thereafter 1

Special Populations

Renal Impairment

Mild impairment (CrCl 50-80 mL/min):

• Day 1: 156 mg deltoid
• Day 8: 117 mg deltoid
• Maintenance: 78 mg monthly (adjust within 39-156 mg range; maximum 156 mg) 1

Moderate/severe impairment (CrCl <50 mL/min):

• Not recommended 1

Hepatic Impairment

• No dose adjustment needed for mild or moderate impairment
• No data available for severe impairment 2, 4

Drug Interactions

Avoid strong CYP3A4/P-gp inducers (carbamazepine, rifampin, St. John's Wort) during the 1-month dosing interval. If necessary, consider switching to oral paliperidone extended-release tablets 1.

Required Monitoring

While the FDA label doesn't specify detailed monitoring protocols, the 2025 INTEGRATE guidelines emphasize:

• Early assessment of treatment effectiveness (at least 4 weeks at therapeutic dose) 3
• Proactive approach to addressing inadequate efficacy or poor tolerability 3
• Individualized monitoring based on age, gender, ethnicity, comorbidities, concomitant medications, tobacco use, and caffeine use 3
• Metabolic monitoring given paliperidone's side-effect profile (weight gain, metabolic changes)
• Extrapyramidal symptom assessment and periodic re-evaluation of need for EPS medications 1

Critical Pitfalls to Avoid

1. Do not skip tolerability testing in antipsychotic-naive patients—always establish tolerability with oral formulation first
2. Do not use oral supplementation—the loading dose regimen provides adequate plasma levels without oral overlap 2, 4
3. Do not administer intravenously or subcutaneously—intramuscular only 1
4. Do not use incorrect needle size—weight-based selection for deltoid is critical for proper absorption
5. Do not forget to shake vigorously for minimum 10 seconds before administration 1
6. Caution with concomitant risperidone or oral paliperidone—paliperidone is risperidone's active metabolite, creating potential for excessive exposure 1